

## Special Issue

# Immunity and Gastrointestinal Cancer

### Message from the Guest Editor

Immunotherapy approaches have recently provided great benefits to patients affected across the spectrum of gastrointestinal cancers. However, the benefits are still not uniform for all patients, and predictive biomarkers remain limited. To date, only inhibitors of the PD-1 or CTLA-4 immune-checkpoint pathways have garnered regulatory approval in gastrointestinal cancers, highlighting the potential that further research into novel immunotherapy strategies and/or immune pathways may yield more positive outcomes for patients. We are pleased to invite the submission of works covering clinical, translational, and/or basic science topics which contribute to an increased understanding of the intersection between immunity and gastrointestinal cancers. This Special Issue aims to cover multiple facets of both preclinical and clinical research harnessing immune mechanisms to augment anti-tumor responses in all cancers of the gastrointestinal tract. This includes cancers affecting the esophagus, gastroesophageal junction, stomach, small bowel, liver, pancreas, colon, rectum, and anal canal.

---

### Guest Editor

Dr. Joseph Chao

Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA 91010, USA

---

### Deadline for manuscript submissions

closed (25 October 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/108065](https://mdpi.com/si/108065)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)